APP and neoplasm: An important goal in PKC–APP modulator drug design must be to overcome the potential carcinogenic properties of benzolactams/indolactams because TPPB, like TPA and other phorbol esters, may still retain tumor-promoting activity (Kozikowski et al. 2003).